array(40) {
  [0]=>
  string(4) "8651"
  ["article_id"]=>
  string(4) "8651"
  [1]=>
  string(76) "Professor's coronavirus tracker app gets 1 million downloads in 48 hours"
  ["article_title"]=>
  string(76) "Professor's coronavirus tracker app gets 1 million downloads in 48 hours"
  [2]=>
  string(150) "The entrepreneurial professor behind the infamous TwinsUK study and ZOE personalised nutrition app has led the creation of a COVID Symptom Tracker app"
  ["short_description"]=>
  string(150) "The entrepreneurial professor behind the infamous TwinsUK study and ZOE personalised nutrition app has led the creation of a COVID Symptom Tracker app"
  [3]=>
  string(210) "The entrepreneurial professor behind the infamous TwinsUK study and ZOE personalised nutrition app has led the creation of a COVID Symptom Tracker app to bolster scientific knowledge into how the virus spreads."
  ["description"]=>
  string(210) "The entrepreneurial professor behind the infamous TwinsUK study and ZOE personalised nutrition app has led the creation of a COVID Symptom Tracker app to bolster scientific knowledge into how the virus spreads."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(176) "https://www.nutraingredients.com/Article/2020/03/26/Professor-s-coronavirus-tracker-app-gets-1-million-downloads-in-48-hours?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(176) "https://www.nutraingredients.com/Article/2020/03/26/Professor-s-coronavirus-tracker-app-gets-1-million-downloads-in-48-hours?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-03-26 19:09:00"
  ["add_date"]=>
  string(19) "2020-03-26 19:09:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:33"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8693"
  ["article_id"]=>
  string(4) "8693"
  [1]=>
  string(54) "Medical grade plastics to be produced using wind power"
  ["article_title"]=>
  string(54) "Medical grade plastics to be produced using wind power"
  [2]=>
  string(150) "Plastic fabrication company, Melitek, has signed an agreement to switch all of its energy consumption to renewable supply, according to the Renewable "
  ["short_description"]=>
  string(150) "Plastic fabrication company, Melitek, has signed an agreement to switch all of its energy consumption to renewable supply, according to the Renewable "
  [3]=>
  string(183) "Plastic fabrication company, Melitek, has signed an agreement to switch all of its energy consumption to renewable supply, according to the Renewable Energy Certificate System (RECS)."
  ["description"]=>
  string(183) "Plastic fabrication company, Melitek, has signed an agreement to switch all of its energy consumption to renewable supply, according to the Renewable Energy Certificate System (RECS)."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(96) "https://www.medicalplasticsnews.com/news/medical-grade-plastics-to-be-produced-using-wind-power/"
  ["blog_url"]=>
  string(96) "https://www.medicalplasticsnews.com/news/medical-grade-plastics-to-be-produced-using-wind-power/"
  [15]=>
  string(19) "2020-03-26 17:32:05"
  ["add_date"]=>
  string(19) "2020-03-26 17:32:05"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:40"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8669"
  ["article_id"]=>
  string(4) "8669"
  [1]=>
  string(81) "Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel"
  ["article_title"]=>
  string(81) "Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel"
  [2]=>
  string(150) "Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough dru"
  ["short_description"]=>
  string(150) "Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough dru"
  [3]=>
  string(399) "Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough drugs. That’s the message life sciences experts shared this week during a webcast on the topic of “oncology’s next decade” recorded for the BIO-Europe Spring partnering conference. The event is produced by EBD Group, […]"
  ["description"]=>
  string(399) "Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough drugs. That’s the message life sciences experts shared this week during a webcast on the topic of “oncology’s next decade” recorded for the BIO-Europe Spring partnering conference. The event is produced by EBD Group, […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(117) "https://xconomy.com/boston/2020/03/26/oncology-needs-combo-therapies-more-data-analysis-says-bio-europe-spring-panel/"
  ["blog_url"]=>
  string(117) "https://xconomy.com/boston/2020/03/26/oncology-needs-combo-therapies-more-data-analysis-says-bio-europe-spring-panel/"
  [15]=>
  string(19) "2020-03-26 15:52:57"
  ["add_date"]=>
  string(19) "2020-03-26 15:52:57"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:33"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8694"
  ["article_id"]=>
  string(4) "8694"
  [1]=>
  string(44) "EU Commission to postpone MDR implementation"
  ["article_title"]=>
  string(44) "EU Commission to postpone MDR implementation"
  [2]=>
  string(150) "The European Commission has announced its intention to postpone the implementation of the new Medical Device Regulation (MDR) following the Coronaviru"
  ["short_description"]=>
  string(150) "The European Commission has announced its intention to postpone the implementation of the new Medical Device Regulation (MDR) following the Coronaviru"
  [3]=>
  string(161) "The European Commission has announced its intention to postpone the implementation of the new Medical Device Regulation (MDR) following the Coronavirus outbreak."
  ["description"]=>
  string(161) "The European Commission has announced its intention to postpone the implementation of the new Medical Device Regulation (MDR) following the Coronavirus outbreak."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(86) "https://www.medicalplasticsnews.com/news/eu-commission-to-postpone-mdr-implementation/"
  ["blog_url"]=>
  string(86) "https://www.medicalplasticsnews.com/news/eu-commission-to-postpone-mdr-implementation/"
  [15]=>
  string(19) "2020-03-26 15:35:48"
  ["add_date"]=>
  string(19) "2020-03-26 15:35:48"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:40"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8652"
  ["article_id"]=>
  string(4) "8652"
  [1]=>
  string(59) "Hospital turns to high-dose vitamin C to fight coronavirus "
  ["article_title"]=>
  string(59) "Hospital turns to high-dose vitamin C to fight coronavirus "
  [2]=>
  string(150) "A hospital has reportedly turned to vitamin C as a treatment for the coronavirus, after reports emerged from China that doses well in excess of daily "
  ["short_description"]=>
  string(150) "A hospital has reportedly turned to vitamin C as a treatment for the coronavirus, after reports emerged from China that doses well in excess of daily "
  [3]=>
  string(196) "A hospital has reportedly turned to vitamin C as a treatment for the coronavirus, after reports emerged from China that doses well in excess of daily Dietary Reference Values (DRV) showed promise."
  ["description"]=>
  string(196) "A hospital has reportedly turned to vitamin C as a treatment for the coronavirus, after reports emerged from China that doses well in excess of daily Dietary Reference Values (DRV) showed promise."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(162) "https://www.nutraingredients.com/Article/2020/03/26/Hospital-turns-to-high-dose-vitamin-C-to-fight-coronavirus?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(162) "https://www.nutraingredients.com/Article/2020/03/26/Hospital-turns-to-high-dose-vitamin-C-to-fight-coronavirus?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-03-26 14:00:00"
  ["add_date"]=>
  string(19) "2020-03-26 14:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:33"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8631"
  ["article_id"]=>
  string(4) "8631"
  [1]=>
  string(86) "Despite failures, chemo still promising against dangerous childhood brain cancer, DIPG"
  ["article_title"]=>
  string(86) "Despite failures, chemo still promising against dangerous childhood brain cancer, DIPG"
  [2]=>
  string(150) "The pediatric brain cancer known as diffuse intrinsic pontine glioma (DIPG) is almost uniformly fatal. In part, this is due to where and how it grows,"
  ["short_description"]=>
  string(150) "The pediatric brain cancer known as diffuse intrinsic pontine glioma (DIPG) is almost uniformly fatal. In part, this is due to where and how it grows,"
  [3]=>
  string(574) "The pediatric brain cancer known as diffuse intrinsic pontine glioma (DIPG) is almost uniformly fatal. In part, this is due to where and how it grows, forming as a diffuse net of cells in a part of the brainstem called the pons, which controls essential functions like breathing and swallowing. Another factor that makes DIPG especially dangerous is a lack of treatments - currently, there are no targeted therapies or immunotherapies proven effective to treat the condition, and the many chemotherapy clinical trials seeking to treat DIPG have been uniformly unsuccessful. "
  ["description"]=>
  string(574) "The pediatric brain cancer known as diffuse intrinsic pontine glioma (DIPG) is almost uniformly fatal. In part, this is due to where and how it grows, forming as a diffuse net of cells in a part of the brainstem called the pons, which controls essential functions like breathing and swallowing. Another factor that makes DIPG especially dangerous is a lack of treatments - currently, there are no targeted therapies or immunotherapies proven effective to treat the condition, and the many chemotherapy clinical trials seeking to treat DIPG have been uniformly unsuccessful. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200325212207.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200325212207.htm"
  [15]=>
  string(19) "2020-03-26 09:22:07"
  ["add_date"]=>
  string(19) "2020-03-26 09:22:07"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8632"
  ["article_id"]=>
  string(4) "8632"
  [1]=>
  string(109) "Modelling study estimates impact of physical distancing measures on progression of COVID-19 epidemic in Wuhan"
  ["article_title"]=>
  string(109) "Modelling study estimates impact of physical distancing measures on progression of COVID-19 epidemic in Wuhan"
  [2]=>
  string(150) "A new study suggests extending school and workplace closures in Wuhan until April, rather than March, would likely delay a second wave of cases until "
  ["short_description"]=>
  string(150) "A new study suggests extending school and workplace closures in Wuhan until April, rather than March, would likely delay a second wave of cases until "
  [3]=>
  string(208) "A new study suggests extending school and workplace closures in Wuhan until April, rather than March, would likely delay a second wave of cases until later in the year, relieving pressure on health services. "
  ["description"]=>
  string(208) "A new study suggests extending school and workplace closures in Wuhan until April, rather than March, would likely delay a second wave of cases until later in the year, relieving pressure on health services. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200325212154.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200325212154.htm"
  [15]=>
  string(19) "2020-03-26 09:21:54"
  ["add_date"]=>
  string(19) "2020-03-26 09:21:54"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8585"
  ["article_id"]=>
  string(4) "8585"
  [1]=>
  string(50) "Gilead Withdraws Orphan Drug Status for Remdesivir"
  ["article_title"]=>
  string(50) "Gilead Withdraws Orphan Drug Status for Remdesivir"
  [2]=>
  string(158) "&#nl        In a surprise move based on public outcry, Gilead asked the FDA to rescind remdesivir’s orphan drug designation as a potential COVID-19 tre"
  ["short_description"]=>
  string(158) "&#nl        In a surprise move based on public outcry, Gilead asked the FDA to rescind remdesivir’s orphan drug designation as a potential COVID-19 tre"
  [3]=>
  string(175) "&#nl        In a surprise move based on public outcry, Gilead asked the FDA to rescind remdesivir’s orphan drug designation as a potential COVID-19 treatment.&#nl      "
  ["description"]=>
  string(175) "&#nl        In a surprise move based on public outcry, Gilead asked the FDA to rescind remdesivir’s orphan drug designation as a potential COVID-19 treatment.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(90) "https://www.fdanews.com/articles/196392-gilead-withdraws-orphan-drug-status-for-remdesivir"
  ["blog_url"]=>
  string(90) "https://www.fdanews.com/articles/196392-gilead-withdraws-orphan-drug-status-for-remdesivir"
  [15]=>
  string(19) "2020-03-26 08:22:30"
  ["add_date"]=>
  string(19) "2020-03-26 08:22:30"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:06"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8670"
  ["article_id"]=>
  string(4) "8670"
  [1]=>
  string(67) "Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments"
  ["article_title"]=>
  string(67) "Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments"
  [2]=>
  string(155) "Regenacy Pharmaceuticals, a biotech formed as part of Celgene’s acquisition of Acetylon Pharmaceuticals in late 2016, has raised $30 million in Seri"
  ["short_description"]=>
  string(155) "Regenacy Pharmaceuticals, a biotech formed as part of Celgene’s acquisition of Acetylon Pharmaceuticals in late 2016, has raised $30 million in Seri"
  [3]=>
  string(389) "Regenacy Pharmaceuticals, a biotech formed as part of Celgene’s acquisition of Acetylon Pharmaceuticals in late 2016, has raised $30 million in Series A financing to move its lead program into a Phase 2 proof-of-concept trial this year. The Waltham, MA-based company is developing treatments to address the underlying cause of peripheral neuropathies—a form of nerve […]"
  ["description"]=>
  string(389) "Regenacy Pharmaceuticals, a biotech formed as part of Celgene’s acquisition of Acetylon Pharmaceuticals in late 2016, has raised $30 million in Series A financing to move its lead program into a Phase 2 proof-of-concept trial this year. The Waltham, MA-based company is developing treatments to address the underlying cause of peripheral neuropathies—a form of nerve […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(105) "https://xconomy.com/boston/2020/03/25/regenacy-pharma-raises-30m-for-nerve-function-restoring-treatments/"
  ["blog_url"]=>
  string(105) "https://xconomy.com/boston/2020/03/25/regenacy-pharma-raises-30m-for-nerve-function-restoring-treatments/"
  [15]=>
  string(19) "2020-03-26 07:08:38"
  ["add_date"]=>
  string(19) "2020-03-26 07:08:38"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:33"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8586"
  ["article_id"]=>
  string(4) "8586"
  [1]=>
  string(55) "New York Judge Dismisses Novartis Gilenya Kickback Suit"
  ["article_title"]=>
  string(55) "New York Judge Dismisses Novartis Gilenya Kickback Suit"
  [2]=>
  string(153) "&#nl        A New York federal judge has dismissed a whistleblower suit alleging that Novartis paid physicians kickbacks to prescribe its multiple-sclero"
  ["short_description"]=>
  string(153) "&#nl        A New York federal judge has dismissed a whistleblower suit alleging that Novartis paid physicians kickbacks to prescribe its multiple-sclero"
  [3]=>
  string(180) "&#nl        A New York federal judge has dismissed a whistleblower suit alleging that Novartis paid physicians kickbacks to prescribe its multiple-sclerosis drug Gilenya.&#nl      "
  ["description"]=>
  string(180) "&#nl        A New York federal judge has dismissed a whistleblower suit alleging that Novartis paid physicians kickbacks to prescribe its multiple-sclerosis drug Gilenya.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(95) "https://www.fdanews.com/articles/196385-new-york-judge-dismisses-novartis-gilenya-kickback-suit"
  ["blog_url"]=>
  string(95) "https://www.fdanews.com/articles/196385-new-york-judge-dismisses-novartis-gilenya-kickback-suit"
  [15]=>
  string(19) "2020-03-26 06:07:00"
  ["add_date"]=>
  string(19) "2020-03-26 06:07:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:06"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8680"
  ["article_id"]=>
  string(4) "8680"
  [1]=>
  string(61) "Graphite-embedded plastic kills 99.99% of bacteria on contact"
  ["article_title"]=>
  string(61) "Graphite-embedded plastic kills 99.99% of bacteria on contact"
  [2]=>
  string(153) "&#nlPlastic surfaces embedded with graphite nanoplatelets reportedly can prevent hospital-acquired infections (HAIs), killing 99.99% of bacteria that try"
  ["short_description"]=>
  string(153) "&#nlPlastic surfaces embedded with graphite nanoplatelets reportedly can prevent hospital-acquired infections (HAIs), killing 99.99% of bacteria that try"
  [3]=>
  string(5085) "&#nl
Plastic surfaces embedded with graphite nanoplatelets reportedly can prevent hospital-acquired infections (HAIs), killing 99.99% of bacteria that try to attach, according to research from Chalmers University of Technology in Sweden.
&#nl&#nl&#nl
Human cells are around 25 times larger than bacteria (pictured here in green). While the graphite nanoplatelets slash and kill bacteria, they barely scratch a human cell. Image courtesy Chalmers University of Technology.
​At any given time, 7% of hospital patients in developed countries and 10% in developing economies will contract at least one HAI, according to the World Health Organization. In Europe, more than four million people are infected annually, according to the European Centre for Disease Prevention and Control. Many of these are bacterial infections that develop around medical devices and implants within the body, such as catheters, hip and knee prostheses or dental implants. In some cases, the implants need to be removed.
&#nl
It is also worth noting that bacterial infections are treated with antibiotics, which accelerates the development of antibiotic resistance.
&#nl
“The purpose of our research is to develop antibacterial surfaces which can reduce the number of infections and subsequent need for antibiotics, and to which bacteria cannot develop resistance,” said Santosh Pandit, postdoctoral researcher in the research group of Professor Ivan Mijakovic at the Division of Systems Biology, Department of Biology and Biotechnology, Chalmers University of Technology. “We have now shown that tailored surfaces formed of a mixture of polyethylene and graphite nanoplatelets can kill 99.99% of bacteria that try to attach to the surface.”
&#nl
Previous studies from the Chalmers researchers showed how vertical flakes of graphene, placed on the surface of an implant, could form a protective coating, making it impossible for bacteria to attach, like spikes on buildings designed to prevent birds from nesting. The graphene flakes damage the cell membrane, killing the bacteria. Producing the graphene flakes is expensive, however, and currently is not feasible for large-scale production. The researchers have achieved the same effect using relatively inexpensive graphite nanoplatelets, mixed with a very versatile polymer.
&#nl
“The polymer is not inherently compatible with the graphite nanoplatelets,” said Roland Kádár, Associate Professor at the Department of Industrial and Materials Science at Chalmers. “But with standard plastic manufacturing techniques, we succeeded in tailoring the microstructure of the material, with rather high filler loadings, to achieve the desired effect. And now it has great potential for a number of biomedical applications,” said Kádár.
&#nl
The nanoplatelets on the surface of the implants prevent bacterial infection without damaging healthy human cells. Human cells are around 25 times larger than bacteria, so while the graphite nanoplatelets slash and kill bacteria, they barely scratch a human cell. 
&#nl
The researchers experimented with different concentrations of graphite nanoplatelets and the plastic material. A composition of around 15 to 20% graphite nanoplatelets proved to have the greatest antibacterial effect, providing that the morphology is highly structured. Precise orientation and distribution of the graphite nanoplatelets is necessary to achieve the maximum effect, according to Kádár.
&#nl
The study was a collaboration between the Division of Systems and Synthetic Biology at the Department of Biology and Biological Engineering, and the Division of Engineering Materials at the Department of Industrial and Materials Science at Chalmers, and medical device company Wellspect Healthcare. The antibacterial surfaces were developed by Karolina Gaska when she was a postdoctoral researcher in the group of Associate Professor Roland Kádár. 
&#nl
The research has been published in the scientific journal Small.
"
  ["description"]=>
  string(5085) "&#nl
Plastic surfaces embedded with graphite nanoplatelets reportedly can prevent hospital-acquired infections (HAIs), killing 99.99% of bacteria that try to attach, according to research from Chalmers University of Technology in Sweden.
&#nl&#nl&#nl
Human cells are around 25 times larger than bacteria (pictured here in green). While the graphite nanoplatelets slash and kill bacteria, they barely scratch a human cell. Image courtesy Chalmers University of Technology.
​At any given time, 7% of hospital patients in developed countries and 10% in developing economies will contract at least one HAI, according to the World Health Organization. In Europe, more than four million people are infected annually, according to the European Centre for Disease Prevention and Control. Many of these are bacterial infections that develop around medical devices and implants within the body, such as catheters, hip and knee prostheses or dental implants. In some cases, the implants need to be removed.
&#nl
It is also worth noting that bacterial infections are treated with antibiotics, which accelerates the development of antibiotic resistance.
&#nl
“The purpose of our research is to develop antibacterial surfaces which can reduce the number of infections and subsequent need for antibiotics, and to which bacteria cannot develop resistance,” said Santosh Pandit, postdoctoral researcher in the research group of Professor Ivan Mijakovic at the Division of Systems Biology, Department of Biology and Biotechnology, Chalmers University of Technology. “We have now shown that tailored surfaces formed of a mixture of polyethylene and graphite nanoplatelets can kill 99.99% of bacteria that try to attach to the surface.”
&#nl
Previous studies from the Chalmers researchers showed how vertical flakes of graphene, placed on the surface of an implant, could form a protective coating, making it impossible for bacteria to attach, like spikes on buildings designed to prevent birds from nesting. The graphene flakes damage the cell membrane, killing the bacteria. Producing the graphene flakes is expensive, however, and currently is not feasible for large-scale production. The researchers have achieved the same effect using relatively inexpensive graphite nanoplatelets, mixed with a very versatile polymer.
&#nl
“The polymer is not inherently compatible with the graphite nanoplatelets,” said Roland Kádár, Associate Professor at the Department of Industrial and Materials Science at Chalmers. “But with standard plastic manufacturing techniques, we succeeded in tailoring the microstructure of the material, with rather high filler loadings, to achieve the desired effect. And now it has great potential for a number of biomedical applications,” said Kádár.
&#nl
The nanoplatelets on the surface of the implants prevent bacterial infection without damaging healthy human cells. Human cells are around 25 times larger than bacteria, so while the graphite nanoplatelets slash and kill bacteria, they barely scratch a human cell. 
&#nl
The researchers experimented with different concentrations of graphite nanoplatelets and the plastic material. A composition of around 15 to 20% graphite nanoplatelets proved to have the greatest antibacterial effect, providing that the morphology is highly structured. Precise orientation and distribution of the graphite nanoplatelets is necessary to achieve the maximum effect, according to Kádár.
&#nl
The study was a collaboration between the Division of Systems and Synthetic Biology at the Department of Biology and Biological Engineering, and the Division of Engineering Materials at the Department of Industrial and Materials Science at Chalmers, and medical device company Wellspect Healthcare. The antibacterial surfaces were developed by Karolina Gaska when she was a postdoctoral researcher in the group of Associate Professor Roland Kádár. 
&#nl
The research has been published in the scientific journal Small.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(82) "https://www.mddionline.com/graphite-embedded-plastic-kills-9999-bacteria-contact-0"
  ["blog_url"]=>
  string(82) "https://www.mddionline.com/graphite-embedded-plastic-kills-9999-bacteria-contact-0"
  [15]=>
  string(19) "2020-03-26 06:00:01"
  ["add_date"]=>
  string(19) "2020-03-26 06:00:01"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:39"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8559"
  ["article_id"]=>
  string(4) "8559"
  [1]=>
  string(82) "Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation"
  ["article_title"]=>
  string(82) "Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation"
  [2]=>
  string(150) "March 25, 2020 -- Gilead has submitted a request to the U.S. Food and Drug Administration to rescind the orphan drug designation it was granted for th"
  ["short_description"]=>
  string(150) "March 25, 2020 -- Gilead has submitted a request to the U.S. Food and Drug Administration to rescind the orphan drug designation it was granted for th"
  [3]=>
  string(249) "March 25, 2020 -- Gilead has submitted a request to the U.S. Food and Drug Administration to rescind the orphan drug designation it was granted for the investigational antiviral remdesivir for the treatment of COVID-19 and is waiving all benefits..."
  ["description"]=>
  string(249) "March 25, 2020 -- Gilead has submitted a request to the U.S. Food and Drug Administration to rescind the orphan drug designation it was granted for the investigational antiviral remdesivir for the treatment of COVID-19 and is waiving all benefits..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(246) "https://www.drugs.com/clinical_trials/gilead-sciences-statement-request-rescind-remdesivir-orphan-designation-18468.html?utm_source=ddc&utm_medium=rss&utm_campaign=Gilead+Sciences+Statement+on+Request+to+Rescind+Remdesivir+Orphan+Drug+Designation"
  ["blog_url"]=>
  string(246) "https://www.drugs.com/clinical_trials/gilead-sciences-statement-request-rescind-remdesivir-orphan-designation-18468.html?utm_source=ddc&utm_medium=rss&utm_campaign=Gilead+Sciences+Statement+on+Request+to+Rescind+Remdesivir+Orphan+Drug+Designation"
  [15]=>
  string(19) "2020-03-26 05:03:43"
  ["add_date"]=>
  string(19) "2020-03-26 05:03:43"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}